Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TFEB antisense RNA 1 (TFEB-AS1) is proposed to be a long non-coding RNA (lncRNA) transcribed antisense to the TFEB gene. While antisense RNAs can sometimes regulate the expression of their sense counterparts at the transcriptional or post-transcriptional level, there is currently no authoritative published evidence describing the biological role, disease association, or therapeutic targeting of TFEB-AS1. Most referenced TFEB research focuses on TFEB protein as a transcription factor involved in autophagy, lysosomal biogenesis, and cellular metabolism[1][2][3][5]. Therefore, TFEB-AS1 should not be considered a canonical protein target, receptor, or enzyme, and—without further information—it is not established as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TFEB antisense RNA 1 (TFEB-AS1).